he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
详细信息信源地址
- 2022-04-2820130704山东卫视养生:杨红宣谈癫痫病的治疗原理
- 2022-04-212013年国际抗癫痫联合会抗癫痫药物使用指南
- 2022-04-20卒于中后癫痫首选用药有哪些?解答卒于中后癫痫的4大问题
- 2022-04-13预测癫痫患者再入院风险
- 2022-04-12控制癫痫患者再次抽搐,不包括可选药物?
- 2022-04-11病例学习:伴皮层下囊肿的巨脑性脑白质病
- 控制癫痫患者再次抽搐,不包括可选药物?
- 病例学习:伴皮层下囊肿的巨脑性脑白质病
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫治疗障碍仍难以克服
- 月经性癫痫患者妊娠期癫痫控制更好
- 癫痫患者手术评估新型工具
- 上海率先探索异地就医门诊费直接结算
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 抗癫痫药物预防新发癫痫:任重而道远
- 北京癫痫手术费用
- 癫痫猝死:凶手是谁?
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 什么是治疗癫痫 癫痫有这些偏方?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 三庚酸酯可治疗1型转运体缺陷综合征
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- FDA警告怀孕期间使用丙戊酸钠药物
- 癫痫的常见症状是什么?
- 2013国际抗癫痫联合会抗癫痫药用指南
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 癫痫诊断的依据是什么?
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 黑芝麻的营养价值 吃黑芝麻的好处
- 2016AAN:神经专家发表了有前途的专业见解
- 癫痫治愈费用
- 上海:1月20日起无偿献血者临床用血费用直接减免
- FDA对怀孕后曾使用丙戊酸钠类药物发出警告
- 大咖直播—6 大公益援助详解:国际癫痫关爱日,患者最高可获 10 万元手术服务费减免
- 【用药详述】失神发作型癫痫的首选药物?
- 怎么用科学的法则治疗癫痫病
- 癫痫发作的症状及医务人员措施
- 导致小儿癫痫病发病诱因有哪些
- 手术学习:内镜下经三脑室入路治疗颅内脊索突起
- 临床试验方案修订对临床试验结果和费用的负面影响
- 惊厥性癫痫持续状态如何正确用药?最近共识告诉你
- 首次癫痫发作需不需要疗程?
- 癫痫病的病患要了解什么症状
- 症状性病症治疗费用要多少钱